

Churg-Strauss Syndrome (also known as Eosinophilic Granulomatosis with Polyangiitis – EGPA) is a rare autoimmune disease that causes inflammation of small and medium-sized blood vessels. It can affect multiple organs, especially the lungs, skin, nerves, and heart. The condition often begins with asthma-like allergic symptoms and may progress to serious complications if not diagnosed early.In this comprehensive guide on Dalili Medical, we reveal everything you need to know about Churg-Strauss Syndrome — including its symptoms, causes, stages, complications, diagnostic methods, treatment options (both medical and herbal), as well as prevention tips and frequently asked questions.
???? If you suffer from chronic asthma or unexplained immune symptoms, this article may contain life-saving information for you.
Churg-Strauss Syndrome (also known as EGPA) is a rare autoimmune disease that causes inflammation of small- and medium-sized blood vessels. It commonly affects the lungs, skin, peripheral nerves, and heart. It often begins with asthma or chronic allergic symptoms.
It can be serious and potentially life-threatening, especially if not diagnosed and treated early. Heart or kidney involvement may lead to severe complications. However, early treatment improves outcomes and can lead to long-term remission.
There is no definitive cure yet, but medications like corticosteroids and immunosuppressants (e.g., rituximab) can effectively control the disease and maintain long periods of stability.
Yes, light exercises such as walking or breathing exercises are encouraged — as long as the disease is stable and approved by a doctor to avoid overexertion.
Yes, it can. Planning pregnancy with a doctor is essential to adjust medications and protect the baby. Some treatments like rituximab and cyclophosphamide are not safe during pregnancy.
Some anti-inflammatory herbs like turmeric and ginger may support treatment, but they are not substitutes for prescribed medications. A doctor-supervised diet plan is recommended.
EGPA is uniquely associated with chronic asthma, high eosinophil levels, and nerve inflammation — distinguishing it from Microscopic Polyangiitis (MPA) and Granulomatosis with Polyangiitis (GPA).
Churg-Strauss Syndrome (EGPA) is a rare autoimmune condition where the immune system mistakenly attacks small and medium blood vessels, causing inflammation in organs such as the lungs, heart, digestive tract, and nerves.
There is no single known cause, but the main trigger appears to be immune system dysfunction, including:
High levels of eosinophils (a type of white blood cell).
Formation of granulomas (clusters of immune cells in tissues).
Abnormal immune response that damages blood vessels.
Factor | Possible Role |
---|---|
Chronic asthma or allergic sinusitis | Over 90% of EGPA patients have a long history of asthma or nasal allergies. |
Genetic predisposition | Certain gene mutations like HLA-DRB4 may increase risk. |
Environmental triggers | Exposure to chemicals, pollutants, or smoke may activate the disease. |
Some asthma medications | Drugs like Montelukast may be linked in rare cases. |
Infections | Viral or bacterial infections may trigger abnormal immune responses in genetically susceptible individuals. |
⚠️ Important Note:
EGPA is not contagious and is not directly inherited, but it is more common in families with a history of autoimmune diseases.
EGPA is classified by clinical phases rather than genetic types. The disease usually progresses through three stages:
Persistent asthma that’s hard to control.
Chronic sinus inflammation or allergic rhinitis.
This phase may last for years before other symptoms appear.
Marked increase in eosinophils in blood and tissues.
May cause:
Eosinophilic pneumonia
Gastrointestinal symptoms (e.g., diarrhea, abdominal pain)
Muscle or subcutaneous inflammation
The most dangerous stage, where blood vessel inflammation begins.
Can lead to:
Peripheral neuropathy (numbness, tingling, muscle weakness)
Kidney or heart inflammation
Skin rashes or even brain involvement
ANCA (Anti-Neutrophil Cytoplasmic Antibodies) testing helps classify the disease in some patients:
More commonly associated with nerve and kidney involvement.
Clinical features resemble other vasculitides like GPA (Granulomatosis with Polyangiitis) and MPA (Microscopic Polyangiitis).
Tends to cause more severe involvement of the heart, lungs, and gastrointestinal tract.
Often associated with high eosinophil counts.
EGPA (Eosinophilic Granulomatosis with Polyangiitis) can cause severe complications if left undiagnosed or untreated, as it affects small- and medium-sized blood vessels supplying vital organs.
One of the most serious risks in EGPA:
Myocarditis (inflammation of the heart muscle)
Heart failure
Arrhythmias (irregular heartbeat)
???? Cardiac issues are among the leading causes of death in EGPA patients.
Due to nerve inflammation and blood vessel damage:
Peripheral neuropathy: Numbness, tingling, weakness in hands or feet
Rarely: Seizures or loss of consciousness
If untreated, can lead to kidney failure:
Glomerulonephritis
Progressive loss of kidney function or chronic renal failure
Since EGPA often begins with respiratory symptoms:
Pulmonary hemorrhage (bleeding in the lungs)
Lung fibrosis if treatment is delayed
Severe asthma attacks
Immunosuppressive drugs and steroids are essential but may cause:
Osteoporosis
Frequent infections due to immune suppression
Stomach ulcers, digestive issues
Weight gain or steroid-induced diabetes
Skin problems or permanent scarring
Severe weight loss and chronic fatigue
High blood pressure (due to kidney damage or medications)
Early diagnosis through blood tests, ANCA screening, and biopsies
Strict adherence to treatment plans by a rheumatologist or immunologist
Regular monitoring of heart, lungs, and kidney function
Healthy lifestyle, stress reduction, and a balanced diet
EGPA typically progresses through three clinical stages, beginning with asthma-like respiratory symptoms and potentially advancing to life-threatening inflammation.
This is the initial stage, which may last for years and serves as an early warning sign:
Chronic allergic asthma (seen in 90%+ of patients)
Chronic sinusitis
Allergic rhinitis (runny nose, sneezing, nasal congestion)
Postnasal drip
⚠️ Asthma that doesn’t respond to treatment may be the first sign of EGPA.
Marked by a rise in eosinophil levels in the blood and tissues, causing:
Persistent cough
Shortness of breath
Chest pain
Pneumonia-like inflammation
Abdominal pain, diarrhea, and occasionally intestinal bleeding
Rarely: muscle inflammation or subcutaneous nodules
The most dangerous stage, where direct inflammation of blood vessels begins, leading to organ damage.
Numbness, tingling, or muscle weakness
May progress to localized paralysis (especially the peroneal nerve)
✅ Key sign: asymmetric multiple peripheral neuropathy
Rashes (purplish or bleeding spots)
Painful nodules or ulcers
Glomerulonephritis
Kidney failure in advanced cases
Myocarditis
Arrhythmias
Heart failure
Certain laboratory tests can strongly support a diagnosis of Eosinophilic Granulomatosis with Polyangiitis (EGPA):
Marked eosinophilia (>10% of total white blood cells)
Positive ANCA test (especially p-ANCA / MPO) in 40–60% of cases
Elevated inflammatory markers: ESR and CRP
Anemia or thrombocytopenia in some cases
Diagnosing EGPA can be challenging due to its overlap with other immune-related conditions like allergic asthma, systemic lupus, or vasculitis. Accurate diagnosis requires a combination of clinical history, lab tests, imaging, and biopsy.
The process begins with reviewing symptoms and medical history. Common indicators include:
Chronic asthma or long-standing sinusitis
Skin rashes, weight loss, nerve pain, or shortness of breath
General fatigue or chronic exhaustion
Laboratory tests help identify inflammation and eosinophil elevation:
Test | Clinical Significance |
---|---|
Eosinophil count | Marked elevation (>10%) is a hallmark of EGPA |
ANCA test | Positive in 40–60% (mostly p-ANCA/MPO subtype) |
ESR and CRP | Indicators of active systemic inflammation |
???? The combination of positive ANCA and eosinophilia significantly strengthens the diagnosis.
Used to assess internal organ involvement, especially the kidneys:
Urinalysis: to detect blood or protein
Liver and kidney function tests: to check for organ damage due to inflammation
Imaging helps evaluate damage to the lungs and nervous system:
Chest X-ray or CT scan: to detect infiltrates or pulmonary fibrosis
MRI or CT of brain/peripheral nerves: to assess nerve inflammation or neurological complications
Often considered the most definitive diagnostic tool:
Tissue biopsy from skin, nerves, or lungs may reveal:
Vasculitis (inflamed blood vessels)
Eosinophilic infiltration in tissues
Formation of granulomas
The American College of Rheumatology (ACR) has outlined 6 criteria. Diagnosis is likely when 4 or more of the following are present:
Asthma
Eosinophilia >10%
Nerve symptoms (e.g., peripheral neuropathy)
Transient pulmonary infiltrates
Sinusitis
Biopsy showing eosinophils or vasculitis
⚠️ No single test can confirm EGPA. Diagnosis requires a holistic approach combining symptoms, lab results, and clinical judgment by a rheumatologist or immunologist.
Treatment aims to suppress the immune system, reduce inflammation, and protect vital organs, based on disease severity.
The first-line treatment in all cases.
Prednisone is typically started at a high dose and tapered gradually.
Helps reduce inflammation and lower eosinophil counts.
Used when major organs like the heart or kidneys are affected:
Cyclophosphamide: for severe, life-threatening cases
Rituximab: an effective alternative, especially in ANCA-positive patients
Methotrexate or Azathioprine: for milder cases or maintenance therapy
Mepolizumab: targets eosinophils and is useful in patients with severe asthma or persistent eosinophilia
Asthma management (bronchodilators, inhalers)
Gastrointestinal and bone protection (antacids, Vitamin D, calcium)
Treatment of cardiovascular or neurological symptoms if present
Frequent blood tests (CBC, eosinophils, kidney function)
Imaging (chest X-ray, ECG) depending on symptoms
Ongoing assessment for side effects of medications or disease complications
Engaging in light, controlled physical activity can help support lung function, reduce stiffness, and improve overall well-being for EGPA patients.
Enhance lung function and improve oxygen intake.
How to do it: Inhale deeply through your nose, hold for 3 seconds, then exhale slowly through your mouth.
⏱ Duration: 5–10 minutes daily
Help reduce joint stiffness and maintain flexibility.
How to do it: Gently stretch each major muscle group (back, shoulders, legs) for 10–15 seconds.
Boosts circulation, mood, and cardiovascular health.
???? Recommended: 20–30 minutes, 3 to 5 times per week
Improves balance, reduces stress, and enhances breathing techniques.
Useful for muscle weakness due to corticosteroid use.
Tips: Use light resistance tools like resistance bands.
High-intensity workouts or exercising during active disease flare-ups.
Any activity causing chest pain or severe shortness of breath.
Exercising without prior approval from your physician.
Herbs should never replace medical treatment but can be used as supportive therapy under professional guidance.
A powerful anti-inflammatory agent.
Usage: 1 teaspoon daily with milk or in meals.
Improves circulation and reduces nausea.
Usage: Ginger tea twice daily.
A natural calming herb that promotes better sleep.
Usage: 1 cup in the evening before bed.
Has corticosteroid-like effects.
⚠️ Warning: Use cautiously, as it may raise blood pressure.
Acts as a natural antihistamine, helpful in asthma and allergic reactions.
Usage: As herbal tea, under medical supervision.
Ephedra (Ma Huang): May cause high blood pressure and heart issues.
Ginkgo Biloba: Increases risk of bleeding.
Echinacea: May overstimulate the immune system, worsening autoimmune diseases.
Never stop your prescribed medications without medical advice.
Always consult your doctor before using any herbal supplement.
Herbs are complementary— not a substitute for standard therapy.
Although there's no guaranteed way to prevent EGPA due to its autoimmune nature, the following steps may help reduce the risk of symptom development or complications:
EGPA often develops years after chronic asthma or nasal allergies.
Proper and early asthma management reduces disease risk.
See your doctor if asthma symptoms worsen or change.
Quit smoking.
Limit exposure to dust, strong perfumes, and chemical irritants.
Use caution with certain medications (e.g., Montelukast), especially if new or unusual symptoms appear.
If you have severe asthma or an autoimmune condition:
Don’t skip your regular check-ups.
Early detection allows treatment adjustments before complications arise.
Eat a balanced diet rich in antioxidants (fruits, vegetables).
Ensure proper intake of essential vitamins and minerals.
Get enough quality sleep and rest.
Practice stress-reducing techniques like meditation, walking, or breathing exercises.
If asthma isn’t responding to treatment or strange symptoms (like skin rashes or nerve pain) occur:
Request blood tests, especially eosinophil count and inflammatory markers, to catch EGPA early.